{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:25:50Z","timestamp":1757456750382,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01906-4","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T09:03:02Z","timestamp":1631523782000},"page":"5302-5316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis"],"prefix":"10.1007","volume":"38","author":[{"given":"Martin","family":"Bergman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishvas","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"1906_CR1","unstructured":"COVID-19 Coronavirus pandemic. https:\/\/www.worldometers.info\/coronavirus\/#countries. Accessed 22 June 2021."},{"key":"1906_CR2","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home. Accessed 19 Jan 2021."},{"key":"1906_CR3","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/j.jaad.2020.03.056","volume":"82","author":"P Shah","year":"2020","unstructured":"Shah P, Zampella JG. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol. 2020;82:e203\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"1906_CR4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","volume":"69","author":"M Czeisler","year":"2020","unstructured":"Czeisler M, Marynak K, Clarke KEN, et al. Delay or avoidance of medical care because of COVID-19-Related Concerns\u2014United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1250\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1906_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79:859\u201366.","journal-title":"Ann Rheum Dis"},{"key":"1906_CR6","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2665-9913(20)30095-3","volume":"2","author":"MA Gianfrancesco","year":"2020","unstructured":"Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol. 2020;2:e250\u20133.","journal-title":"Lancet Rheumatol"},{"key":"1906_CR7","unstructured":"American Academy of Dermatology Association. Guidance on the use of immunosuppressive agents. https:\/\/www.aad.org\/member\/practice\/coronavirus\/clinical-guidance\/biologics Accessed 26 Feb 2021."},{"key":"1906_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/art.41301","volume":"72","author":"TR Mikuls","year":"2020","unstructured":"Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol. 2020;72:1241\u201351.","journal-title":"Arthritis Rheumatol"},{"key":"1906_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","volume":"159","author":"DT Rubin","year":"2020","unstructured":"Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159:350\u20137.","journal-title":"Gastroenterology"},{"key":"1906_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jaad.2020.09.001","volume":"83","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol. 2020;83:1704\u201316.","journal-title":"J Am Acad Dermatol"},{"key":"1906_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2020.06.051","volume":"83","author":"O Zahedi Niaki","year":"2020","unstructured":"Zahedi Niaki O, Anadkat MJ, Chen ST, et al. Navigating immunosuppression in a pandemic: a guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. J Am Acad Dermatol. 2020;83:1150\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1906_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3899\/jrheum.201017","volume":"48","author":"MD George","year":"2021","unstructured":"George MD, Venkatachalam S, Banerjee S, et al. Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. J Rheumatol. 2021;48:603\u20137.","journal-title":"J Rheumatol"},{"key":"1906_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.21315\/mjms2018.25.4.12","volume":"25","author":"MA Bujang","year":"2018","unstructured":"Bujang MA, Sa\u2019at N, Sidik T, Joo LC. Sample size guidelines for logistic regression from observational studies with large population: emphasis on the accuracy between statistics and parameters based on real life clinical data. Malays J Med Sci. 2018;25:122\u201330.","journal-title":"Malays J Med Sci"},{"key":"1906_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","volume":"20","author":"G Schett","year":"2020","unstructured":"Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20:271\u20132.","journal-title":"Nat Rev Immunol"},{"key":"1906_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.semarthrit.2020.06.017","volume":"50","author":"B Mehta","year":"2020","unstructured":"Mehta B, Jannat-Khah D, Mancuso CA, et al. Geographical variations in COVID-19 perceptions and patient management: a national survey of rheumatologists. Semin Arthritis Rheum. 2020;50:1049\u201354.","journal-title":"Semin Arthritis Rheum"},{"key":"1906_CR16","doi-asserted-by":"publisher","first-page":"e14516","DOI":"10.1111\/dth.14516","volume":"33","author":"V Brazzelli","year":"2020","unstructured":"Brazzelli V, Isoletta E, Barak O, et al. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone. Dermatol Ther. 2020;33:e14516.","journal-title":"Dermatol Ther"},{"key":"1906_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/BOR.0000000000000725","volume":"32","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol. 2020;32:434\u201340.","journal-title":"Curr Opin Rheumatol"},{"key":"1906_CR18","doi-asserted-by":"crossref","unstructured":"Ansarin K, Taghizadieh A, Safiri S, et al. COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs. Ann Rheum Dis. 2020.","DOI":"10.1136\/annrheumdis-2020-218737"},{"key":"1906_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"R Haberman","year":"2020","unstructured":"Haberman R, Axelrad J, Chen A, et al. COVID-19 in immune-mediated inflammatory diseases\u2014case series from New York. N Engl J Med. 2020;383:85\u20138.","journal-title":"N Engl J Med"},{"key":"1906_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13075-020-02395-6","volume":"22","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Bugatti S, Klersy C, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020;22:290.","journal-title":"Arthritis Res Ther"},{"key":"1906_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","volume":"79","author":"C Sanchez-Piedra","year":"2020","unstructured":"Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79:988\u201390.","journal-title":"Ann Rheum Dis"},{"key":"1906_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-020-00927-y","volume":"41","author":"E Monreal","year":"2021","unstructured":"Monreal E, de la Maza SS, Fern\u00e1ndez-Velasco JI, et al. The impact of Immunosuppression and autoimmune disease on severe outcomes in patients hospitalized with COVID-19. J Clin Immunol. 2021;41:315\u201323.","journal-title":"J Clin Immunol"},{"key":"1906_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","volume":"82","author":"M Lebwohl","year":"2020","unstructured":"Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82:1217\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1906_CR24","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","volume":"19","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19:102523.","journal-title":"Autoimmun Rev"},{"key":"1906_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","volume":"38","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38:337\u201342.","journal-title":"Clin Exp Rheumatol"},{"key":"1906_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"1906_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","volume":"76","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43\u20139.","journal-title":"Eur J Intern Med"},{"key":"1906_CR28","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325\u201331.","journal-title":"Lancet Rheumatol"},{"key":"1906_CR29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","volume":"79","author":"E Della-Torre","year":"2020","unstructured":"Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79:1277\u201385.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01906-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T07:37:52Z","timestamp":1725781072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01906-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}